In:
Cancer, Wiley, Vol. 125, No. 21 ( 2019-11), p. 3790-3800
Abstract:
In this randomized comparative phase 2 trial in patients with recurrent glioblastoma, the combination of the Src inhibitor dasatinib with bevacizumab was found to lead to a 6‐month progression‐free survival rate that was numerically but not statistically higher than that noted with single‐agent bevacizumab. The addition of dasatinib also resulted in a significantly longer response duration, but no difference in survival.
Type of Medium:
Online Resource
ISSN:
0008-543X
,
1097-0142
DOI:
10.1002/cncr.v125.21
Language:
English
Publisher:
Wiley
Publication Date:
2019
detail.hit.zdb_id:
1479932-7
detail.hit.zdb_id:
2599218-1
detail.hit.zdb_id:
2594979-2
detail.hit.zdb_id:
1429-1
Permalink